ANB 020

Drug Profile

ANB 020

Alternative Names: ANB020

Latest Information Update: 14 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator AnaptysBio
  • Class Antiallergics; Antiasthmatics; Antibodies; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Interleukin 1 receptor-like 1 protein antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis; Peanut hypersensitivity
  • Phase I Asthma

Most Recent Events

  • 10 Aug 2017 UK MHRA approves clinical trial application for ANB 020 in Asthma (Severe eosinophilic asthma)
  • 10 Aug 2017 AnaptysBio completes enrolment in its phase IIa trial for Atopic dermatitis in United Kingdom
  • 11 May 2017 AnaptysBio filed an CTA application with the MHRA in United Kingdom for Eosinophilic asthma before May 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top